Akoya Biosciences Announces Commercial Launch of PhenoCycler-Fusion, the Fastest Single-Cell Spatial Biology System

NEXT STORY
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
PREV STORY
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle’s Growing Biotech Hub

author_avatar
NASDAQ Market News

American Kidney Fund Appoints Five New Members to Board of Trustees

ROCKVILLE, Maryland, March 02, 2018 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF), the ...

author_avatar
NASDAQ Market News

FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

author_avatar
NASDAQ Market News